Released : Jun 01, 2018

RNS Number : 9304P

Tiziana Life Sciences PLC

01 June 2018

 

 

Tiziana Life Sciences plc

 

Annual Report and Accounts and Notice of Annual General Meeting

 

Tiziana Life sciences plc ("Company") announces that its Annual General Meeting will be held at 10:00 a.m. on Monday 25 June 2018 at the offices of Cooley (UK) LLP, Dashwood, 69 Old Broad Street, London EC2M 1QS.

 

In connection with this, the following documents will be posted to shareholders shortly:

 

· Notice of Annual General Meeting; and

 

· Proxy Form.

 

The Annual Report and Accounts for the year ended 31 December 2017 ("Annual Report") will be despatched to shareholders shortly under separate cover.

 

Copies of the Notice of Annual General Meeting will be available to view on the Company's website at  www.tizianalifesciences.com.

 

Contacts

 

Tiziana Life Sciences plc

Gabriele Cerrone, Chairman and founder                               +44 (0)20 7493 2853

 

 

Cairn Financial Advisers LLP (Nominated Adviser)

Liam Murray / Jo Turner                                                            +44 (0)20 7213 0880

 

 

About Tiziana

 

Tiziana is a UK biotechnology company that focuses on the discovery and development of novel molecules that treat human disease in oncology and immunology. The Company is focused on its lead compound milciclib. The Company is also in clinical development of foralumab. Foralumab is the only fully human engineered human anti-CD3 antibody in clinical development. This phase II compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), primary biliary cholangitis (PBS), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), inflammatory bowel disease (IBD), psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable.

 

For more information go to http://www.tizianalifesciences.com 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

 

END

 

 

NOASDDFWFFASEFI